What is the initial management of non‑ST‑segment elevation myocardial infarction (NSTEMI)?

Initial Management of NSTEMI

Immediately administer aspirin (162-325 mg loading dose) and initiate dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor 180 mg loading dose preferred, or clopidogrel 600 mg if ticagrelor unavailable), along with anticoagulation therapy, while simultaneously performing risk stratification to determine timing of invasive strategy. 1, 2

Immediate Actions (Within 10 Minutes)

Antiplatelet Therapy

• Aspirin: 162-325 mg loading dose immediately, continue 81 mg daily indefinitely 1, 2
• P2Y12 Inhibitor (choose one):
  • Ticagrelor 180 mg loading dose (preferred option, 90 mg twice daily maintenance) 1, 2
  • Clopidogrel 600 mg loading dose (75 mg daily maintenance) if ticagrelor contraindicated 1, 2
  • For aspirin-allergic patients: Use P2Y12 inhibitor alone 1

Anticoagulation (Choose One)

Start immediately alongside antiplatelet therapy 3, 2:

• Enoxaparin: 1 mg/kg SC every 12 hours (Level of Evidence: A)
• Fondaparinux: 2.5 mg SC daily (preferred if increased bleeding risk) (Level of Evidence: B)
• UFH: 60 IU/kg bolus (max 4000 IU), then 12 IU/kg/hr infusion (max 1000 IU/hr), adjusted to aPTT (Level of Evidence: B)
• Bivalirudin: 0.10 mg/kg bolus, then 0.25 mg/kg/hr (only for early invasive strategy) (Level of Evidence: B)

Critical caveat: If fondaparinux is used and PCI is performed, add UFH or bivalirudin during the procedure due to catheter thrombosis risk 2

Risk Stratification and Invasive Strategy Timing

Very High-Risk Features (Immediate Invasive <2 Hours) 4

Proceed to catheterization immediately if ANY of the following present:

• Hemodynamic instability or cardiogenic shock
• Recurrent or refractory chest pain despite medical therapy
• Life-threatening arrhythmias (ventricular tachycardia/fibrillation)
• Mechanical complications (acute mitral regurgitation, ventricular septal defect)
• Acute heart failure
• Recurrent dynamic ST-segment or T-wave changes

High-Risk Features (Early Invasive <24 Hours) 2, 4

Proceed to catheterization within 24 hours if:

• GRACE risk score >140 1, 4
• Elevated troponin levels
• Dynamic ECG changes (ST-depression, T-wave inversions)
• Diabetes mellitus
• Renal insufficiency (eGFR <60 mL/min/1.73m²)
• Prior MI, PCI, or CABG
• Reduced left ventricular ejection fraction (<40%)

The 2014 AHA/ACC guidelines strongly support early invasive strategy (within 24 hours) for high-risk patients, with the most recent 2025 guidelines reinforcing this approach 2, 5

Ischemia-Guided Strategy (Conservative Approach)

For low-risk patients without high-risk features 2:

• Continue dual antiplatelet therapy and anticoagulation
• Perform stress testing before discharge
• If stress test positive or recurrent symptoms develop → proceed to angiography

Additional Pharmacotherapy

Anti-Ischemic Therapy

• Beta-blockers: Initiate within 24 hours if no contraindications (heart failure, bradycardia, hypotension) 3
• Nitroglycerin: Sublingual or IV for ongoing chest pain 6
• Morphine: 2-4 mg IV for pain relief if nitroglycerin insufficient 6
• ACE inhibitor or ARB: Start within 24 hours, especially if anterior MI, heart failure, or LVEF <40% 3
• High-intensity statin: Initiate immediately (atorvastatin 80 mg or rosuvastatin 40 mg) 2

GP IIb/IIIa Inhibitors

Consider adding eptifibatide or tirofiban 1, 2:

• Before PCI in very high-risk patients with ongoing ischemia
• At time of PCI if large thrombus burden
• Avoid abciximab unless PCI is imminent 7

Key Management Pitfalls to Avoid

1. Do NOT use prasugrel before coronary anatomy is known; only give after PCI decision is made 1, 8
2. Do NOT use fibrinolytic therapy in NSTEMI—this is Class III harm 2
3. Do NOT delay aspirin while waiting for troponin results 1
4. Do NOT use dual P2Y12 inhibitors together (e.g., clopidogrel + ticagrelor) 1
5. Do NOT forget additional anticoagulation if fondaparinux used and patient goes to PCI 2

Special Considerations for CABG Planning

If CABG becomes necessary 1:

• Continue aspirin throughout
• Stop clopidogrel 5 days before surgery
• Stop prasugrel 7 days before surgery
• Stop ticagrelor 5 days before surgery
• Stop GP IIb/IIIa inhibitors 4 hours before surgery
• Stop enoxaparin 12-24 hours before, switch to UFH
• Stop fondaparinux 24 hours before, switch to UFH
• Stop bivalirudin 3 hours before, switch to UFH

Duration of Therapy

• Aspirin: Indefinitely 1, 2
• P2Y12 inhibitor: Minimum 12 months regardless of revascularization strategy 1, 2
• Anticoagulation: Continue until discharge or up to 8 days if conservative strategy 3, 1

The evidence strongly supports that high-risk NSTEMI patients benefit most from early invasive strategy within 24 hours, particularly those with GRACE score >140, as demonstrated in the TIMACS and VERDICT trials 1, 4